News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,417 Results
Type
Article (739)
Company Profile (1)
Press Release (7677)
Multimedia
Podcasts (6)
Webinars (1)
Section
Business (2769)
Career Advice (16)
Deals (378)
Drug Delivery (6)
Drug Development (1283)
Employer Resources (3)
FDA (257)
Job Trends (159)
News (4613)
Policy (354)
Tag
Academia (31)
Accelerated approval (4)
ADA (3)
Alliances (959)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (9)
Approvals (265)
Artificial intelligence (12)
ASCO (3)
Autoimmune disease (5)
Automation (2)
Bankruptcy (10)
Best Places to Work (94)
BIOSECURE Act (1)
Biosimilars (20)
Biotechnology (1)
Bladder cancer (1)
Breast cancer (9)
Cancer (90)
Cardiovascular disease (7)
Career advice (15)
Cell therapy (7)
Clinical research (1100)
Collaboration (72)
Compensation (5)
COVID-19 (14)
C-suite (29)
Cystic fibrosis (6)
Data (72)
Diabetes (8)
Diagnostics (46)
Digital health (4)
Drug discovery (3)
Drug pricing (21)
Earnings (792)
Editorial (1)
Employer branding (1)
Employer resources (2)
Events (843)
Executive appointments (23)
FDA (293)
Funding (31)
Generative AI (2)
Gene therapy (8)
GLP-1 (71)
Government (58)
Guidances (5)
Healthcare (140)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (1)
Immunology and inflammation (10)
Immuno-oncology (1)
Indications (3)
Infectious disease (18)
Inflammatory bowel disease (5)
Inflation Reduction Act (1)
Influenza (2)
Intellectual property (2)
Interviews (4)
IPO (179)
IRA (10)
Job creations (69)
Job search strategy (15)
Labor market (2)
Layoffs (13)
Legal (83)
Lung cancer (39)
Machine learning (2)
Management (1)
Manufacturing (12)
MASH (16)
Medical device (74)
Medtech (75)
Mergers & acquisitions (195)
Metabolic disorders (56)
mRNA (5)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (33)
NextGen: Class of 2026 (70)
Non-profit (36)
Now hiring (1)
Obesity (37)
Opinion (7)
Ovarian cancer (1)
Parkinson's disease (3)
Patents (4)
People (976)
Pharmacy benefit managers (3)
Phase 1 (261)
Phase 2 (449)
Phase 3 (414)
Pipeline (121)
Policy (16)
Postmarket research (115)
Preclinical (87)
Rare diseases (14)
Real estate (72)
Recruiting (1)
Regulatory (281)
Reports (1)
Research institute (29)
Resumes & cover letters (1)
RNA editing (1)
Schizophrenia (10)
Series A (9)
Series B (6)
Special edition (1)
Startups (62)
Supply chain (1)
The Weekly (6)
Vaccines (11)
Venture capital (4)
Weight loss (31)
Date
Last 7 days (10)
Last 30 days (26)
Last 365 days (328)
2026 (177)
2025 (318)
2024 (413)
2023 (371)
2022 (667)
2021 (669)
2020 (584)
2019 (520)
2018 (377)
2017 (536)
2016 (489)
2015 (451)
2014 (374)
2013 (333)
2012 (325)
2011 (309)
2010 (336)
Location
Africa (19)
Alabama (1)
Arizona (4)
Asia (268)
Australia (66)
California (255)
Canada (8)
China (8)
Colorado (1)
Connecticut (28)
Europe (2290)
Florida (2)
Georgia (8)
Illinois (10)
India (2)
Indiana (9)
Japan (8)
Kansas (1)
Maryland (2)
Massachusetts (57)
Michigan (3)
Missouri (1)
Nevada (1)
New Hampshire (1)
New Jersey (12)
New York (15)
North Carolina (6)
Northern California (66)
Ohio (1)
Oklahoma (1)
Oregon (1)
Pennsylvania (8)
South America (21)
Southern California (135)
Tennessee (1)
Texas (5)
United States (435)
Utah (1)
Virginia (1)
Washington D.C. (2)
Washington State (16)
8,417 Results for "boehringer ingelheim fremont".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.
June 4, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
June 11, 2026
·
5 min read
Press Releases
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
·
14 min read
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
May 12, 2026
·
3 min read
Press Releases
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
April 13, 2026
·
4 min read
Press Releases
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
June 8, 2026
·
18 min read
Press Releases
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
April 9, 2026
·
4 min read
Press Releases
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
April 20, 2026
·
4 min read
1 of 842
Next
